The phase 3 clinical trial evaluating use of tirzepatide — the drug’s generic name — injection (5 mg, 10 mg or 15 mg) in adults with heart failure with preserved ejection fraction and obesity. The trial lasted for 52 weeks.
The study found patients on Mounjaro injections were less likely to be hospitalized, less likely to increase their heart failure medication or die of heart complications, and had fewer symptoms such as shortness of breath, fatigue, and swelling of the lower legs, according to an Aug. 1 company news release.
The results have not been peer reviewed.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
